Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines.

Autor:	Joseph JH; Clinical Testing of Beverly Hills, Beverly Hills, CA, USA., Maas C, Palm MD, Lain E, Glaser DA; Department of Dermatology, Saint Louis University School of Medicine, St. Louis, MO, USA., Bruce S, Yoelin S, Cox SE, Fagien S, Sangha S; Research and Development, Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA., Maltman J; Research and Development, Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA., Lei X; Research and Development, Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA., Brin MF; Research and Development, Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA.
Jazyk:	angličtina
Zdroj:	Aesthetic surgery journal [Aesthet Surg J] 2022 Oct 13; Vol. 42 (11), pp. 1318-1327.
DOI:	10.1093/asj/sjac157
Abstrakt:	Background: OnabotulinumtoxinA 20 U reduces glabellar line (GL) severity at maximum frown for approximately 3 to 4 months. Small studies have suggested that >20-U doses may increase the efficacy and duration of response for GLs. Objectives: The aim of this study was to evaluate safety, pharmacodynamic response, and treatment satisfaction with onabotulinumtoxinA doses ≥20 U for GLs. Methods: This 48-week, double-blind study compared 40, 60, and 80 U onabotulinumtoxinA vs 20 U and placebo in women with moderate or severe dynamic GLs on the Allergan Facial Wrinkle Scale. The following parameters were evaluated: the percentage of subjects with investigator-assessed ≥1-grade Facial Wrinkle Scale improvement from baseline at maximum frown (responders) at Week 24; the estimated median duration of response; the proportion of mostly/very satisfied responders on the Facial Line Satisfaction Questionnaire follow-up Items 1 to 5; and treatment-emergent adverse events. Results: The modified intent-to-treat population (N = 226) had a mean age of 48.0 years, with similar baseline GL severity between treatment groups. Week 24 responder rates were 0% for placebo and 16.0%, 32.0%, 30.6%, and 38.5% for onabotulinumtoxinA 20, 40, 60, and 80 U, with significant (P < 0.05) differences for 40 and 80 U vs 20 U. Median duration of response was longer with all higher doses vs 20 U (≥24.0 vs 19.7 weeks; P < 0.05 vs 20 U at Week 24). Facial Line Satisfaction Questionnaire results indicated high subject satisfaction. The incidence and severity of treatment-emergent adverse events did not exhibit a dose-response effect. Conclusions: GL treatment with onabotulinumtoxinA doses >20 U demonstrated longer duration of response and higher patient-reported satisfaction vs the on-label 20-U dose with no apparent impact on safety variables. (© 2022 The Aesthetic Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu